Type
Internal restructuring
Country
Germany
Region
Location of affected unit(s)
Sector
Manufacturing
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21.1 - Manufacture Of Basic Pharmaceutical Products

250 jobs
Number of planned job losses
Job loss
Announcement Date
2 June 2022
Employment effect (start)
Foreseen end date

Description

The German medical technology company Fresenius Kabi, a subsidiary of the German pharmaceutical company Fresenius, has announced plans to cut 250 jobs in Germany.

As part of its efficiency programme, the Fresenius Group plans to cut a total of about 2,000 jobs worldwide in its drug and nutrition division Fresenius Kabi. The company did not want to comment on the figures and stated that it is currently working on details of a costs and efficiency programme to further strengthen competitiveness. As of June 2022, it is unknown when the job losses will be implemented by.

The world restructuring programme for Fresenius Kabi is recorded in the ERM Fresenius Kabi-2022-WO. In November 2021, the dialysis subsidiary Fresenius Medical Care had already announced the reduction of 5000 jobs worldwide, of which about 500 to 750 jobs in Germany, see Fresenius Medical Care-2021-DE and Fresenius Medical Care-2021-WO.


Sources

Citation

Eurofound (2022), Fresenius Kabi, Internal restructuring in Germany, factsheet number 106949, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/106949.